advertisement
Hu Y 22
Showing records 1 to 22 |
Display all abstracts from Hu Y98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual functionFang F
Molecular Therapy 2022; 30: 1421-1431
98269 Measures of disease activity in glaucomaWu Y
Biosensors & bioelectronics 2022; 196: 113700
98642 TGF-β2-induced circ-PRDM5 regulates migration, invasion, and EMT through the miR-92b-3p/COL1A2 pathway in human lens epithelial cellsHuang P
Journal of molecular histology 2022; 53: 309-320
99075 Long-term visual outcomes of primary congenital glaucoma in ChinaFang L
Ophthalmic Research 2022; 0:
98269 Measures of disease activity in glaucomaSzymanska M
Biosensors & bioelectronics 2022; 196: 113700
99075 Long-term visual outcomes of primary congenital glaucoma in ChinaHu Y
Ophthalmic Research 2022; 0:
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual functionZhuang P
Molecular Therapy 2022; 30: 1421-1431
98642 TGF-β2-induced circ-PRDM5 regulates migration, invasion, and EMT through the miR-92b-3p/COL1A2 pathway in human lens epithelial cellsHu Y; Duan Y
Journal of molecular histology 2022; 53: 309-320
99075 Long-term visual outcomes of primary congenital glaucoma in ChinaZhong Y
Ophthalmic Research 2022; 0:
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual functionFeng X
Molecular Therapy 2022; 30: 1421-1431
98269 Measures of disease activity in glaucomaHu Y; Fazal MI
Biosensors & bioelectronics 2022; 196: 113700
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual functionLiu P
Molecular Therapy 2022; 30: 1421-1431
99075 Long-term visual outcomes of primary congenital glaucoma in ChinaXiao H
Ophthalmic Research 2022; 0:
98269 Measures of disease activity in glaucomaJiang N
Biosensors & bioelectronics 2022; 196: 113700
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual functionLiu D
Molecular Therapy 2022; 30: 1421-1431
99075 Long-term visual outcomes of primary congenital glaucoma in ChinaLin S; Zhu Y
Ophthalmic Research 2022; 0:
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual functionHuang H
Molecular Therapy 2022; 30: 1421-1431
98269 Measures of disease activity in glaucomaYetisen AK; Cordeiro MF
Biosensors & bioelectronics 2022; 196: 113700
99075 Long-term visual outcomes of primary congenital glaucoma in ChinaSu Y
Ophthalmic Research 2022; 0:
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual functionLi L; Chen W
Molecular Therapy 2022; 30: 1421-1431
99075 Long-term visual outcomes of primary congenital glaucoma in ChinaLiu X
Ophthalmic Research 2022; 0:
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual functionLiu L; Sun Y; Jiang H; Ye J; Hu Y
Molecular Therapy 2022; 30: 1421-1431